---
title: "J.P. Morgan Reaffirms Their Buy Rating on RemeGen Co. Ltd. Class H (9995)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295287684.md"
description: "J.P. Morgan analyst Yang Huang reaffirmed a Buy rating on RemeGen Co. Ltd. Class H (9995) with a HK$129 price target, despite shares closing at HK$79.50. This contrasts with the broader market consensus of Moderate Buy and an average target of HK$120.78."
datetime: "2026-08-08T00:26:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295287684.md)
  - [en](https://longbridge.com/en/news/295287684.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295287684.md)
generator: "portal-rs"
---

# J.P. Morgan Reaffirms Their Buy Rating on RemeGen Co. Ltd. Class H (9995)

In a report released on August 6, Yang Huang from J.P. Morgan maintained a Buy rating on RemeGen Co. Ltd. Class H, with a price target of HK$129.00. The company’s shares closed yesterday at HK$79.50.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Huang is ranked #487 out of 12391 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RemeGen Co. Ltd. Class H with a HK$120.78 average price target.

### Related Stocks

- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [RemeGen Shareholders Back All Resolutions at 2025 AGM](https://longbridge.com/en/news/289949552.md)
- [RemeGen Forecasts Major Profit Turnaround on Surging Drug Sales and AbbVie Licensing Deal](https://longbridge.com/en/news/294974949.md)
- [Canadian Life Companies Split declares monthly distribution of $0.1 per Class A share and $0.06 per preferred share](https://longbridge.com/en/news/296359920.md)
- [Dividend 15 Split Corp. II declares monthly distributions of $0.1 for Class A shares, $0.06 for preferred shares](https://longbridge.com/en/news/296360313.md)
- [Klappir publishes investor presentation for Class B share offering at EUR 3.43 per share](https://longbridge.com/en/news/296407110.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**